NCT02576509 · BASELINE

Baseline characteristics

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma · Source last updated 2025-02-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
371
group Id
BG001
value
372
group Id
BG002
value
743
units
Participants

groups

description
Nivolumab 240 mg intravenously (IV) every 2 weeks until disease progression or unacceptable toxicity
id
BG000
title
Nivolumab 240 mg
description
Sorafenib 400 mg orally (PO) twice a day (BID) until disease progression or unacceptable toxicity
id
BG001
title
Sorafenib 400 mg
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
185
group Id
BG001
value
176
group Id
BG002
value
361
title
Between 18 and 65 years
measurements
group Id
BG000
value
186
group Id
BG001
value
196
group Id
BG002
value
382
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
10.61
value
63.9
group Id
BG001
spread
10.91
value
64.5
group Id
BG002
spread
10.76
value
64.2
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
57
group Id
BG001
value
55
group Id
BG002
value
112
title
Female
measurements
group Id
BG000
value
314
group Id
BG001
value
317
group Id
BG002
value
631
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
10
group Id
BG002
value
15
title
Hispanic or Latino
measurements
group Id
BG000
value
180
group Id
BG001
value
170
group Id
BG002
value
350
title
Not Hispanic or Latino
measurements
group Id
BG000
value
186
group Id
BG001
value
192
group Id
BG002
value
378
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
165
group Id
BG001
value
167
group Id
BG002
value
332
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
3
group Id
BG001
value
2
group Id
BG002
value
5
title
Black or African American
measurements
group Id
BG000
value
199
group Id
BG001
value
196
group Id
BG002
value
395
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
4
group Id
BG001
value
6
group Id
BG002
value
10
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants

Complete source fields

denoms

counts
group Id
BG000
value
371
group Id
BG001
value
372
group Id
BG002
value
743
units
Participants

groups

description
Nivolumab 240 mg intravenously (IV) every 2 weeks until disease progression or unacceptable toxicity
id
BG000
title
Nivolumab 240 mg
description
Sorafenib 400 mg orally (PO) twice a day (BID) until disease progression or unacceptable toxicity
id
BG001
title
Sorafenib 400 mg
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
185
group Id
BG001
value
176
group Id
BG002
value
361
title
Between 18 and 65 years
measurements
group Id
BG000
value
186
group Id
BG001
value
196
group Id
BG002
value
382
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
10.61
value
63.9
group Id
BG001
spread
10.91
value
64.5
group Id
BG002
spread
10.76
value
64.2
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
57
group Id
BG001
value
55
group Id
BG002
value
112
title
Female
measurements
group Id
BG000
value
314
group Id
BG001
value
317
group Id
BG002
value
631
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
5
group Id
BG001
value
10
group Id
BG002
value
15
title
Hispanic or Latino
measurements
group Id
BG000
value
180
group Id
BG001
value
170
group Id
BG002
value
350
title
Not Hispanic or Latino
measurements
group Id
BG000
value
186
group Id
BG001
value
192
group Id
BG002
value
378
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
165
group Id
BG001
value
167
group Id
BG002
value
332
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
3
group Id
BG001
value
2
group Id
BG002
value
5
title
Black or African American
measurements
group Id
BG000
value
199
group Id
BG001
value
196
group Id
BG002
value
395
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
4
group Id
BG001
value
6
group Id
BG002
value
10
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice